GlaxoSmithKline Pharmaceuticals Limited (GLAXO) — Announcement | 21 July 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Company announces analyst meeting on August 3, 2026
💡 Investor Takeaway
Investors should note the meeting date may shift and no new financial details will be disclosed.

GlaxoSmithKline Pharmaceuticals announced an analyst and institutional investor meeting scheduled for August 3, 2026, to discuss digital initiatives and share updates already in the public domain, with a note that dates may change due to exigencies.

📄 View Original Announcement (PDF)

About GlaxoSmithKline Pharmaceuticals Limited (GLAXO)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹51,721.36 Cr P/E: 49.2 ROE: 47.1% ROCE: 64.1% Div Yield: 1.87%

View full GLAXO stock details →

📡 Get AI alerts when GLAXO files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track GLAXO — Free

📊 More GLAXO filings

See all GLAXO filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when GLAXO files new disclosures

Track GLAXO filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track GLAXO — Free

Free account · 2 AI queries/day